Thermo Fisher Scientific has announced an agreement to acquire Solventum’s Purification & Filtration business for approximately $4.1 billion in cash. This acquisition enhances Thermo Fisher’s bioproduction business by expanding its capabilities in bioprocessing, complementing its existing portfolio in cell culture media and single-use technologies.

Solventum’s Purification & Filtration business, which generated about $1 billion in revenue in 2024, specializes in purification and filtration technologies used in biologics production, medical technologies, and industrial applications. The business operates globally with approximately 2,500 employees.

Thermo Fisher’s chairman and CEO, Marc N. Casper, emphasized that this acquisition aligns with the company’s strategy of disciplined capital deployment and customer value creation. The transaction, expected to close by the end of 2025, is subject to regulatory approvals. Once completed, the business will be integrated into Thermo Fisher’s Life Sciences Solutions segment.

The acquisition is expected to drive mid- to high-single-digit organic growth and generate approximately $125 million in adjusted operating income from synergies by year five. Thermo Fisher anticipates an initial dilution of $0.06 to adjusted EPS in the first year but expects it to be accretive by $0.28 excluding financing costs.

source: Thermo Fisher Scientific, February 25, 2025.